Related Experiment Video
Updated: Jul 14, 2026

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis
Published on: June 2, 2015
[Venous thrombosis and thrombophilic management of prevention and therapy]
1Medizinische Klinik III/Kardiologie, Angiologie, Pulmologie, Gerinnungsambulanz und Thrombophiliesprechstunde, Universität Heidelberg, Bergheimer Str. 58, 69115 Heidelberg. johannes_ruef@med.uni-heidelberg.de
Insights
Cardiovascular diseases, including venous thrombosis and pulmonary embolism, are leading causes of death. This paper reviews thrombotic risk factors, diagnosis, and management strategies, including new anticoagulants.
Area of Science:
- Cardiology and Hematology
Background:
- Cardiovascular diseases, including venous thrombosis and pulmonary embolism, are primary causes of mortality in industrialized nations.
- Thrombosis stems from temporary risk factors or inherited thrombophilia.
Purpose of the Study:
- To discuss thrombotic risk factors, their significance, and diagnostic approaches.
- To outline prophylaxis and treatment methods for patients with or at risk of thrombosis.
- To review current and novel anticoagulants for thromboembolic complication management.
Main Methods:
- Review of current literature on thrombotic risk factors, diagnostics, and treatment.
- Discussion of the pathophysiology of thrombosis.
- Evaluation of available and emerging anticoagulant therapies.
Main Results:
- Thrombotic risk assessment is enhanced by increased understanding of pathophysiology and advanced diagnostics.
- Various risk factors contribute to thrombosis, necessitating tailored diagnostic and management plans.
- New anticoagulants show potential for effective and cost-efficient patient care.
Conclusions:
- Effective management of thrombosis requires understanding risk factors, accurate diagnosis, and appropriate prophylaxis/treatment.
- Novel anticoagulants offer promising avenues for improving patient outcomes and managing thromboembolic risks.
- A patient-centered and cost-efficient approach is crucial for preventing and treating thromboembolic complications.
Abstract:
Cardiovascular disease, to which venous thrombosis and pulmonary embolism contribute a major part, are the leading cause of death in industrialized countries. Thrombosis is caused by temporary risk factors or by thrombophilia. Increasing knowledge concerning the pathophysiology of thrombosis and new diagnostic tools allow a thrombotic risk assessment. In this paper thrombotic risk factors will be discussed with respect to their significance and diagnosis as well as methods of prophylaxis and treatment for patients at risk for or with diagnosed thrombosis. Furthermore, currently available as well as new anticoagulants (pentasaccharide, melagatran) will be discussed and their potential for patient-oriented and cost-efficient prophylaxis and treatment of thromboembolic complications outlined.
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Venous Thrombosis I: Introduction
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Venous Thrombosis III: Interprofessional Care
Venous Thrombosis IV: Nursing Management
Pulmonary Embolism III: Nursing Management

